Deadline for Case Reports submission: January 2, 2019
Notification of acceptance or rejection: January 7, 2019

Abstract submission deadline has been postponed to 1 February 2019
Notification of acceptance or rejection: February 18, 2019

ABSTRACT SUBMISSION

The Scientific Committee seeks high-quality abstracts to be presented as Poster during the OCT RETINA FORUM 2019.
Participants interested in making a poster presentation are invited to submit an abstract within January 21, 2019. The submitted abstracts will be accepted as Posters and displayed in the exhibition area.

Each Presenting Author/First Author can only submit a maximum of two abstracts.

Submission
Abstract submission will be possible exclusively through our web site

Submit

All abstracts will undergo review by the Abstract Review Committee, to determine which abstracts may be accepted.

Notification of acceptance or rejection will be sent to the corresponding author by February 18, 2019.
Registration is compulsory in order to present an abstract during the Congress.

Topics

▪ Structural Optical Coherence Tomography
▪ En Face Optical Coherence Tomography
▪ Optical Coherence Tomography Angiography
▪ Ultra-High Resolution Macular Imaging
▪ Ultra-Wide Field Retinal Imaging
▪ Functional Imaging
▪ Pathophysiology, Diagnosis & Treatment Of Retinal & Macular Diseases
▪ Age-Related Macular Degeneration
▪ Diabetic Retinopathy
▪ Retinal Vein Occlusion
▪ Retinal Artery Occlusion & Paracentral Acute Middle Maculopathy
▪ Pathologic Myopia
▪ Central Serous Chorio-Retinopathy
▪ Angioid Streaks
▪ Macular Telangiectasia
▪ Retinal & Macular Dystrophies
▪ Surgical Macular Retinal Diseases
▪ Challenging Cases

 

Instructions
Please read carefully the below instructions before submitting your abstract.

• The complete abstract text must not exceed 3.200 characters including spaces (approx. 250 words) therefore, it is important to plan, review and edit your abstract for clarity and concision.
• Abstracts should be submitted in English
Please provide a minimum of 2 and a maximum of 5 specific keywords for scheduling and indexing purposes.
Each abstract should have a brief descriptive title of 20 words maximum. Trademarks are not allowed in the abstract title.
All abbreviations must be defined the first time they appear in the text, before being used as an abbreviation only
Structured abstracts are mandatory. The abstracts should clearly state the Purpose, Methods, Results and Conclusions
Tables, charts or other graphics must be uploaded as images
Please don’t add double information in the text (title, authors and affiliations)
• Generic names must be used for all references to pharmaceutical products
• Please spell check your abstract prior to submission

 

Before you begin, please prepare the following information:


.
Presenting author’s contact details:

• Date of birth
• Affiliation details: Department, iIstitution / Hospital, City, State (if relevant), Country
.
Co-author’s details:
• Full first and family name(s)

Affiliation details: Department, iIstitution / Hospital, City, State (if relevant), Country

.

CASE STUDIES SUBMISSION

Participants are also encouraged to submit Case studies related to retinal diseases.
The Scientific Committee will review and select up to 20 of the submitted cases for presentation.
Accepted cases will be presented by the authors and discussed during a dedicated Scientific Session.
The selected speaker(one of the attendants whose clinical case was choose) will present it.
Deadline for Case Reports submission: January 2, 2019
Case Reports there will be not selected for the Session, will be accepted as Posters.

FORMAT (submit the abstract of your case study and 3-4 slides)

  • Abstracts should be submitted in English.
  • Abstracts are limited to 250 words (excluding title, sub-titles and acknowledgements) therefore, it is important to plan, review and edit your abstract for clarity and concision.
  • Please provide a minimum of 2 and a maximum of 5 specific keywords for scheduling and indexing purposes.
  • Each abstract should have a brief descriptive title of 20 words maximum. Trademarks are not allowed in the abstract title.
  • The following structure should be followed:
    – Introduction
    – Case report
    – Conclusions and discussions
    – Acknowledgements

(Please list all sources of funding of the work described and other acknowledgements)

  • Generic names must be used for all references to pharmaceutical products
  • Please spell check your abstract prior to submission

 

Please submit maximum 4 slides to be presented in 5 minutes on retinal diseases cases. (File types: PowerPoint 2007/2010/2013 (i.e. pptx file)

 

IMPORTANT TO NOTE:

Authors

  • Author names and institutions must be declared. You will be asked to enter the name(s) of the author(s) and their institution(s), when submitting your abstract online.
  • Abstracts should be submitted by first authors who vouch for the standards of research conduct and approval of co-authors for submission.
  • First authors will present or nominate one of the authoring team to present the abstract if selected for presentation.
  • Abstracts will be reviewed by the Review Committee and notice of abstract acceptance or rejection will be e-mailed to the submitting author.

Submission Notification

  • After submitting your case study, you will receive an e-mail confirmation (please make sure to state your correct e-mail address). Should you wish to make corrections to a case study already submitted or if you wish to submit other case studies later, you may use your personal access codes.
  • Corrections to case studies can only be made up to the case study submission deadline.

 

Registration

To be eligible for a case study presentation authors receiving a case study acceptance notification must register and make full payment.

After submitting your abstract, you will receive an e-mail confirmation (please make sure to state your correct e-mail address). Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal access codes until the deadline.

 

For any further information, please contact: octforum2019@aimgroup.eu